OS Therapies (OSTX) announced the issuance of U.S. Patent #12,230,738, protecting commercial manufacturing methods for its listeria monocytogenes cancer immunotherapy platform technology into 2040. The company stated the patent covers its lead asset OST-HER2, Phase 3-stage OST-AXIL, Phase 2-stage OST-503, Phase 1-stage OST-504, and eight pre-clinical candidates, as well as OST-HER2’s use in canine osteosarcoma.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSTX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue